Last update 01 Nov 2024

Arteriosclerosis Obliterans

Last update 01 Nov 2024

Basic Info

Synonyms

ARTERIOSCLEROSIS OBLITERANS, Arteriosclerosis Obliterans, Arteriosclerosis obliterans

+ [11]

Introduction

Common occlusive arterial disease which is caused by ATHEROSCLEROSIS. It is characterized by lesions in the innermost layer (ARTERIAL INTIMA) of arteries including the AORTA and its branches to the extremities. Risk factors include smoking, HYPERLIPIDEMIA, and HYPERTENSION.

Drugs associated with Arteriosclerosis Obliterans

Beperminogene perplasmid

Target

c-Met

Mechanism

c-Met modulators

Active Org.

AnGes, Inc.

Originator Org.

AnGes, Inc.

Active Indication

Arteriosclerosis Obliterans [+1]

Inactive Indication

Chronic Limb-Threatening Ischemia [+3]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date26 Mar 2019

Selexipag

Target

PGI2 receptor

Mechanism

PGI2 receptor agonists

Active Org.

Actelion Pharmaceuticals US, Inc. [+10]

Originator Org.

Nippon Shinyaku Co., Ltd.

Active Indication

Pulmonary Arterial Hypertension [+2]

Inactive Indication

Associated Pulmonary Arterial Hypertension [+5]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date21 Dec 2015

Extract of Ginkgo Biloba Leaves

Target-

Mechanism-

Active Org.

Dr. Willmar Schwabe GmbH & Co. KG

Originator Org.

Dr. Willmar Schwabe GmbH & Co. KG

Active Indication

Arteriosclerosis Obliterans [+3]

Inactive Indication

Asthma

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date17 Apr 2001

Clinical Trials associated with Arteriosclerosis Obliterans

ChiCTR2400088557 / SuspendedIIT

Mechanism of miR-30b-5p promoting ferroptosis of vascular smooth muscle cells and inhibiting arteriosclerosis obliterans

Start Date22 Aug 2024

Sponsor / Collaborator-

NCT06485622 / RecruitingNot ApplicableIIT

Outcome and Improvement of Different Treatment in Arteriosclerosis Obliterans: a Prospective, Single-center, Observational Study

This study is a prospective, single-center, observational study. In this study, we aim to evaluate the clinical outcome and cost-effectiveness of different treatments of lower extremity arterial occlusive disease. It is expected to include about 400 patients diagnosed with lower extremity arterial occlusive disease in our center from July 2024 to July 2026. All enrolled patients will be followed for three years. All patients diagnosed with arteriosclerosis obliterans (ASO) and all treatment techniques were included in this study. The primary outcomes include the Efficacy and Safety End Points of each techniques.

Start Date01 Jul 2024

Sponsor / Collaborator

the First Affiliated Hospital of Sun Yat-Sen University

ChiCTR2400082678 / SuspendedPhase 4IIT

The efficacy and safety of percutaneous transluminal angioplasty (PTA) in the treatment of lower extremity arteriosclerosis obliterans (ASO):Open-label, prospective, multicenter, non-randomized controlled study

Start Date01 May 2024

Sponsor / Collaborator

The First Affiliated Hospital of Zhengzhou University

100 Clinical Results associated with Arteriosclerosis Obliterans

100 Translational Medicine associated with Arteriosclerosis Obliterans

0 Patents (Medical) associated with Arteriosclerosis Obliterans

1,291

Literatures (Medical) associated with Arteriosclerosis Obliterans

26 Aug 2024·World journal of clinical cases

Application of buried auricular point combined with Wenjing Sanhan prescription in arteriosclerosis obliterans patients with resting pain.

Article

Author: Su, Zhi-Hui ; Li, Ya-Ping ; Xue, Xiao-Li ; Su, Tian ; Li, Jun ; Shi, Huan-Ren

BACKGROUNDResearch on the combined use of ear acupoint embedding beans and warming meridians with cold-dispersing formulas for alleviating resting pain in patients with arteriosclerosis obliterans (ASO) remains limited.AIMTo explore the therapeutic efficacy of auricular point embedding beans combined with Wenjing Sanhan prescription in alleviating resting pain in patients with lower-limb ASO.METHODSA total of 100 patients with ASO experiencing resting pain who were treated at our hospital from January 2022 to January 2023 were enrolled. They were randomly allocated into two groups using a double-blind approach. The control group was treated using a warming meridian with a cold-dispersing formula, while the study group received additional treatment with ear acupoint embedding beans. The clinical efficacy, ankle-brachial artery pressure ratio, hemorheological indicators, and traditional Chinese medicine symptom scores were compared between the two groups.RESULTSThe clinical efficacy rate in the study group was significantly higher (94.00%) than that in the control group (72.00%, P < 0.05). Moreover, the ankle-brachial artery pressure ratio was significantly higher in the study group after treatment (P < 0.05). Hemorheological parameters, including whole blood viscosity, plasma viscosity (1.83 ± 0.11) mPa/s, fibrinogen levels (3.30 ± 0.21) g/L, platelet adhesion rate (49.87% ± 10.51%), and erythrocyte aggregation index (1.79 ± 0) were improved in the study group compared to the control group. In addition, the scores for decreased skin temperature (1.41 ± 0.26), intermittent claudication (1.30 ± 0.20), and resting pain (1.23 ± 0.31) were significantly lower in the study group than those in the control group (all P < 0.05). The level of oxidative stress in the study group also exhibited significant improvement (P < 0.05), and the levels of inflammatory factors were considerably lower than those in the control group.CONCLUSIONThe combination of ear point embedding beans and Wenjing Sanhan prescription demonstrates promising clinical efficacy in alleviating resting pain associated with ASO.

14 Aug 2024·Clinical Hemorheology and Microcirculation

Effect of alprostadil plus cilostazol on the treatment outcomes and inflammatory factors in patients with lower extremity arteriosclerosis obliterans receiving evidence-based care

Article

Author: Liu, Yuchen ; Yang, Miao ; Wu, Wei ; Liu, Panwang ; Li, Huafeng ; Di, Panpan ; Liang, Hai

This study aims to elucidate the effect of alprostadil (ALP) plus cilostazol (CIL) on the treatment outcomes and inflammatory factors in patients with lower extremity arteriosclerosis obliterans (LEASO) receiving evidence-based care. Firstly, 130 patients with LEASO were selected from February 2020 to February 2023 and then randomly divided into two groups with 65 patients each. Excluding the dropouts, 59 patients in the control group (6 cases of dropout) received ALP and 62 patients in the research group (3 cases of dropout) received ALP plus CIL. Both groups were cared for in accordance with the evidence-based care model. Treatment outcomes, arteriosclerosis indexes (blood flow of dorsalis pedis artery [DPA], ankle–brachial index [ABI] and toe–brachial index [TBI]), hemorheological parameters (erythrocyte aggregation index [EAI], erythrocyte deformation index [EDI], high blood viscosity [HBV] and haematocrit [HCT]), inflammatory factors (interleukin [IL]-6, IL-8 and tumour necrosis factor [TNF]-α) and complications (nausea, diarrhoea, headache and transaminase elevation) were compared between the control and research groups. Results show that the overall response rate was markedly higher in the research group (90.32%) than in the control group (74.58%). Additionally, the blood flow of DPA, ABI and TBI in the research group significantly increased after the treatment and were higher than those in the control group. Meanwhile, the EAI, EDI, HBV, HCT, IL-6, IL-8 and TNF-α were significantly lower. The two groups did not differ markedly in the complication rate. The above findings suggest that ALP plus CIL is effective for patients with LEASO receiving evidence-based care. It can significantly improve arteriosclerosis indexes and hemorheological parameters while inhibiting serum inflammatory responses, with some certain safety.

01 Aug 2024·The American Journal of Cardiology

Determinants of One-Year Outcome After Successful Percutaneous Coronary Intervention for Chronic Total Occlusion; Insight from Japanese CTO-PCI Expert Registry

Article

Author: Katoh, Harumi ; Oikawa, Yuji ; Hirai, Keisuke ; Muramatsu, Toshiya ; Kawasaki, Tomohiro ; Kishi, Koichi ; Tanaka, Hiroyuki ; Okada, Hisayuki ; Tsuchikane, Etsuo ; Yoshikawa, Ryohei ; Katoh, Osamu

Although outcomes have improved with new-generation drug-eluting stents, few reports have analyzed the risk factors associated with chronic outcomes of chronic total occlusion (CTO)-percutaneous coronary intervention (PCI). This study aimed to investigate the independent risk factors for target lesion revascularization (TLR) and major adverse cardiac and cerebrovascular events (MACCEs) after CTO-PCI using Japanese multicenter data. A total of 3,666 patients, who underwent CTO-PCI and completed a 1-year follow-up, registered at the Japanese CTO-PCI Expert Registry from 2014 to 2019, were examined. The primary outcome was defined as TLR, and the secondary outcome was MACCEs at the 1-year follow-up. TLRs and MACCEs occurred in 175 (4.8%) and 524 (14.3%) patients, respectively. Multivariate logistic regression analysis demonstrated that in-stent occlusion (ISO) (odds ratio [OR] 2.604, 95% confidence interval [CI] 1.695 to 4.001), hemodialysis (OR 1.784, 95% CI 1.062 to 2.997), diabetes mellitus with insulin use (OR 1.741, 95% CI 1.060 to 2.861), moderate-to-severe calcification (OR 1.726, 95% CI 1.197 to 2.487), and the right coronary artery as the target vessel (OR 1.468, 95% CI 1.018 to 2.117) were significantly associated with TLR. Hemodialysis (OR 2.214, 95% CI 1.574 to 3.113), ISO (OR 1.499, 95% CI 1.127 to 1.993), arteriosclerosis obliterans (OR 1.414, 95% CI 1.074 to 1.863), and multivessel disease (OR 1.356, 95% CI 1.117 to 1.647) were significantly associated with MACCEs. One-year outcomes of new-generation drug-eluting stents for CTO-PCI were favorable, and ISO as a lesion factor and hemodialysis as a patient factor were strongly associated with TLR and MACCEs, respectively.

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Arteriosclerosis Obliterans

Basic Info

Related

Analysis